HOME >> BIOLOGY >> NEWS
Combination Therapy For Brain Tumors Holds Promise For Longer Survival After,,Surgery

Combination Therapy for Brain Tumors Holds Promise for Longer Survival After Surgery Despite advances in neuroimaging and surgery, no major developments in the treatment of malignant brain tumors have been introduced in the past two decades. Right now, surgeons rely on radiation therapy after removal of the tumor to mop up microscopic cancerous cells that could lead to regrowth. Brain tumors, however, are extremely resistant to radiation treatment. Researchers at the University of Pennsylvania Medical Center have now found a way to make brain cancer cells more receptive to radiation treatment --by 60-fold in some cases.

"The goal of our research is to extend the survival of terminally ill patients and give them a better quality of life during that time," says Donald M. O'Rourke, MD, assistant professor of neurosurgery. "Following a diagnosis of brain cancer, median survival of patients is only 12 months with treatment." More than 17,000 new cases of brain cancer are reported each year, according to O'Rourke, and this diagnosis is nearly always fatal.

In a biochemical one-two punch to brain cancer cells, O'Rourke and colleagues inactivated a common cell-surface receptor called the Epidermal Growth Factor Receptor (or erbB for short) to arrest cell growth in human cell lines, which further sensitized the cells to radiation. This approach works in a similar way to Herceptin, the new breast-cancer-fighting drug awaiting FDA approval. Herceptin, a monoclonal antibody therapy, is based on the basic research performed by the laboratory of Mark I. Greene, MD, PhD, at Penn. Both strategies target mutated or overexpressed erbB receptor proteins that allow cancer cells to grow unchecked.

"Depending on which type of cell we used, we achieved between 20 and 60 percent cell death in cancer cells where the erbB receptor was first deactivated, versus zero to 5 percent in radiation-alone controls," reports O'Rourke. These findings were pu
'"/>

Contact: Karen Young Kreeger
kreeger@mail.med.upenn.edu
(215) 614-0290
University of Pennsylvania School of Medicine
16-Sep-1998


Page: 1 2

Related biology news :

1. Combination of gene therapy and gene silencing prevents neurodegenerative disease
2. Combination therapy dramatically improves function after spinal cord injury in rats
3. Combination therapy drives cancer into remission
4. Combination drug therapy drastically reduces multiple coronary heart disease risk factors
5. Combination therapy improves anthrax survival
6. Drug Combination May Prove Effective To Prevent Recurrence Of Hepatitis C After Transplantation
7. New Heart-Attack Indicator Dramatically Improves Diagnostic Accuracy Of ER Doctors: TnT/Echocardiogram Combination Could Reduce Needless Admissions
8. Dangerous Chemical Combination Presents Possible Scenario For Gulf War Illnesses
9. 1st International Conference on Cell Therapy for Cardiovascular Disease
10. National Cancer Gene Therapy Foundation gives $4.0 million in research grants
11. Braunschweig Prize 2003 for Molecular Cancer Therapy

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/28/2020)... PRUSSIA, Pa. and CAMBRIDGE, Mass. (PRWEB) , ... ... ... to solving complex problems for life sciences companies and government agencies, announced that ... life sciences hubs in the country. Tunnell’s Cambridge office will be in the ...
(Date:1/27/2020)... ... ... On Thursday, February 20, 2020 at 10am EST (3pm GMT/UK), join Gary ... Castle, Global Account Manager Medical Device at PRISYM ID for an informative ... deadlines, best practices in creating and submitting product data and best practices in preparing ...
(Date:1/24/2020)... ... January 24, 2020 , ... Shoreline Biome , a microbiome research ... announced that the company will debut a novel new DNA isolation kit at the ... product, Shoreline Biome's Rapid Prep kit, is a fast and easy-to-use kit designed for ...
Breaking Biology News(10 mins):
(Date:1/23/2020)... ... January 22, 2020 , ... Ideal Implant ... surgery industry at two recent North American investor forums specializing in medical advancements. ... Medical Technologies & Diagnostics Forum on November 21, 2019 in New York City, ...
(Date:1/10/2020)... ... January 09, 2020 , ... A new report ... for the vendor qualification process, a critical element of clinical trial set up ... of the vendor qualification process creates delays in initiation in 7% of clinical ...
(Date:1/7/2020)... (PRWEB) , ... January 07, 2020 , ... ... antibody products and services, today announced the launch of its VivopureX™ recombinant mouse ... antibody clones, many originally obtained from rats or hamsters, which Absolute Antibody has ...
(Date:12/31/2019)... (PRWEB) , ... December 31, 2019 , ... ... in expanding its pharmaceutical product development lab in Maryland. Emphasis will ... increased size and expanded capabilities, Vici Health Sciences will be well positioned to ...
Breaking Biology Technology:
Cached News: